Relationship of non-alcoholic fatty liver disease in patients with arterial hypertension to certain cardio-metabolic risk factors
https://doi.org/10.25789/YMJ.2024.88.28
Abstract
A study was conducted by type "case" and "control" among the non-indigenous population in south Yakutia with arterial hypertension (AH) in the presence and absence of non-alcoholic fatty liver disease (NAFLD). The groups were comparable in age. Patients in the main group had statistically significantly high systolic blood pressure, average BMI and WC values compared with patients without NAFLD. In hypertensive patients in combination with NAFLD, the chance of developing obesity is more than 4 times higher compared to the control. Hypertensive patients with NAFLD had a significantly high incidence of atherogenic dyslipidemia. The conducted ROC analysis showed the prognostic significance of risk factors such as BMI, OT, TG and blood pressure levels with the risk of developing NAFLD in patients with hypertension.
About the Authors
S. I. Sofronova
ЯНЦ КМП
Russian Federation
Russian Federation
A. N. Romanova
ЯНЦ КМП
Russian Federation
Russian Federation
References
1. Arterial hypertension in adults. Clinical guidelines 2024 / Zh.D. Kobalava, A.O. Konradi, S.V. Nedogoda [et al.] // Russian journal of cardiology. 2024. 9(29). P. 230-329. DOI: 10.15829/1560-4071-2024-6117
2. Cardiovascular prevention 2022. Russian national guidelines / S.A. Boytsov [et al.] // Russian journal of cardiology. 2023. Vol. 28, No. 5. P. 119- 249. DOI:10.15829/1560-4071-2023-5452
3. Clinical guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the Russian Association of Endocrinologists, the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology for the diagnosis and treatment of non-alcoholic fatty liver disease / V.T. Ivashkin, M.V. Mayevskaya, M.S. Zharkova [et al.] // Russian Journal of Gastroenterology, Hepatology, Proctology. 2022. Vol. 32, No. 4. P. 104-140. DOI: 10.22416/1382-4376-2022-32-4-104-140
4. Interdisciplinary clinical guidelines "Treatment of obesity and comorbid diseases" / I.I. Dedov, M.V. Shestakova, G.A. Melnichenko [et al.] // Obesity and Metabolism. 2021. Vol. 18, No. 1. P. 5-99. https://doi.org/10.14341/omet12714
5. Lipid Metabolism Disorders. Clinical Guidelines 2023 / M.V. Yezhov, V.V. Kukharchuk, I.V. Sergienko [et al.] // Russian Journal of Cardiology. 2023. Vol. 28, No. 5. P. 250-297. DOI: 10.15829/1560-4071-2023-5471
6. Aneni EC, Oni ET, Martin SS, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens 2015;33:1207–1214. doi: 10.1097/ HJH.0000000000000532.
7. Ciardullo S, Grassi G, Mancia G, Gianluca P. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis // European Journal of Gastroenterology & Hepatology. 2022; 34(4): 365-371. DOI: 10.1097/MEG.0000000000002299
8. Duell PB, Welty FK, Miller M, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association // Arteriosclerosis, Thrombosis and Vascular Biology. 2022; 42(6):e168-e185. doi: 10.1161/ATV.000000000000015
9. Huang Q, Yu H, Zhong X, Tian Y, Cui Z, Quan Z. Association between hypertension and nonalcoholic fatty liver disease: A cross-sectional and meta-analysis study. J Hum Hypertens 2023;37:313–320. doi: 10.1038/s41371-022-00686-w.
10. Kabbany MN, Conjeevaram Selvakumar PK, Watt K, et al. Prevalence of nonalcoholic steatohepatitis associated cirrhosis in the United States: An analysis of National Health and Nutrition Examination Survey data // Am J Gastroenterol 2017; 112: 581–587. doi: 10.1038/ajg.2017.5
11. Li G, Peng Y, Chen Z, Li H, Liu D, Ye X. Bidirectional association between hypertension and NAFLD: A systematic review and meta-analysis of observational studies // Int J Endocrinol. 2022: 8463640. doi: 10.1155/2022/8463640
12. Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? // J Hepatol. 2018; 68: 335–352. doi: 10.1016/j.jhep.2017.09.021.
13. Quek Jingxuan, Chan Kai En, Wong Zhen Yu, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis // Lancet Gastroenterol Hepatol. 2023; 8(1): 20-30. doi: 10.1016/S2468-1253(22)00317-X
14. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension // European Heart Journal. 2018; 39(33): 3021-3104. https://doi.org/10.1093/eurheartj/ehy339
15. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. 2016; 64: 73–84.
16. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective // Journal of Hepatology. 2019; 70(3): 531-544. https://doi.org/10.1016/j.jhep.2018.10.033
17. Yuan M, He J, Hu Xue, et al. Hypertension and NAFLD risk: Insights from the NHANES 2017-2018 and Mendelian randomization analyses // Observational Study Chin Med J (Engl). 2024;137(4):457-464. doi: 10.1097/CM9.0000000000002753. Epub 2023 Jul 14.
Review
For citations:
Sofronova S.I., Romanova A.N. Relationship of non-alcoholic fatty liver disease in patients with arterial hypertension to certain cardio-metabolic risk factors. Yakut Medical Journal. 2024;(4):118-121. (In Russ.) https://doi.org/10.25789/YMJ.2024.88.28
Views:
16
Email this article 